Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC).

Background: Data are limited addressing anticoagulant reversal in obese patients using activated prothrombin complex concentrate (aPCC).

Objective: Assess the impact of obesity on INR reversal with fixed aPCC dosing.

Methods: Institutional review board-approved, retrospective cohort conducted in a large academic medical center.